Fulcrum Therapeutics, Inc. (FULC) News

Fulcrum Therapeutics, Inc. (FULC): $4.92

0.02 (+0.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FULC to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Filter FULC News Items

FULC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

FULC News Highlights

  • For FULC, its 30 day story count is now at 8.
  • Over the past 17 days, FULC's stories per day has been in a clear uptrend, growing by about 0.23 per 3 days.
  • The most mentioned tickers in articles about FULC are RARE and VCEL.

Latest FULC News From Around the Web

Below are the latest news stories about Fulcrum Therapeutics Inc that investors may wish to consider to help them evaluate FULC as an investment opportunity.

Vericel Corporation (VCEL) Q4 Earnings Miss Estimates

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -47.06% and 0.24%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Fulcrum Therapeutics® to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Thursday, March 3, 2022 at 8:00 a.m. ET

CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its fourth quarter and full year 2021 financial results will be released on Thursday, March 3, 2022 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on rec

Yahoo | February 24, 2022

These 2 Stocks Could Be Bought Out, Says Credit Suisse

The economy continues to recover from the pandemic impact, but the currents are flowing in multiple directions at once. Emblematic of the situation is the combination of high inflation and improving jobs numbers, each tugging in opposite directions on the economy. Still, there are some unequivocal signs of economic health that investors can latch onto. One of these, a boost in buyout activity, presents a particularly interesting set of data. In 2021, the US economy saw buyout transactions worth a total of $2.5 trillion, more than 25% higher than the previous record, 2015’s $1.96 trillion.

Michael Marcus on TipRanks | February 15, 2022

2 ‘Strong Buy’ Stocks That Could Be Bought Out, According to Credit Suisse

The economy continues to recover from the pandemic impact, but the currents are flowing in multiple directions at once. Emblematic of the situation is the combination of high inflation and improving jobs numbers, each tugging in opposite directions on the economy. Still, there are some unequivocal signs of economic health that investors can latch onto. One of these, a boost in buyout activity, presents a particularly interesting set of data. In 2021, the US economy saw buyout transactions worth

Yahoo | February 15, 2022

Multiple insiders bought Fulcrum Therapeutics, Inc. (NASDAQ:FULC) stock earlier this year, a positive sign for shareholders

Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...

Yahoo | February 12, 2022

Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the grant of inducement awards outside of the Company’s 2019 Stock Incentive Plan to Amy Winnen, the Company’s newly appointed Vice President, Head of Market Value, Access and Policy. The grant was approved by a majority of the independent directors of the Compan

Yahoo | February 11, 2022

Fulcrum Therapeutics® to Participate in 11th Annual SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference, on Thursday, February 17, 2022 at 9:20 a.m. ET. A live audio webcast will be available through the Investor Relations section of the Fulcrum website a

Yahoo | February 10, 2022

Monashee Investment Management LLC Buys Vanguard Total Stock Market ETF, Hyperfine Inc, Agree ...

Investment company Monashee Investment Management LLC (Current Portfolio) buys Vanguard Total Stock Market ETF, Hyperfine Inc, Agree Realty Corp, Pardes Biosciences Inc, DocGo Inc, sells Maravai LifeSciences Holdings Inc, SomaLogic Inc, MoneyLion Inc, RBC Bearings Inc, BioAtla Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Monashee Investment Management LLC.

Yahoo | February 7, 2022

Mass General Brigham, Inc Buys DocuSign Inc, Oyster Point Pharma Inc, Dada Nexus, Sells iShares ...

Investment company Mass General Brigham, Inc (Current Portfolio) buys DocuSign Inc, Oyster Point Pharma Inc, Dada Nexus, Airbnb Inc, sells iShares Core S&P 500 ETF, iShares Core U.S.

Yahoo | January 20, 2022

Hedge Funds Are Crazy About Fulcrum Therapeutics, Inc. (FULC)

Last year we predicted the arrival of the first US recession since 2009 and we told in advance that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock […]

Yahoo | January 12, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5008 seconds.